Mahigit 400 COVID-19 patients gumaling matapos makatanggap ng convalescent plasma

By Dona Dominguez-Cargullo September 25, 2020 - 02:03 PM

Mahigit 400 COVID-19 patients ang gumaling matapos sumailalim sa convalescent plasma treatment.

Ayon kay Food and Drug Administration (FDA) Director General Eric Domingo, sa 526 na mga pasyente na napagkalooban ng convalescent blood plasma, 429 ang naka-recover na.

Nagpapakita ito ayon kay Domingo ng “good results” sa experimental treatment ng COVID-19.

Ayon kay Domingo, kailangan pa din ng dagdag na mga pag-aaral para matukoy kung talagang nagagamot ng blood plasma ang COVID-19.

Ang Plasma ay liquid component ng dugo na nagtataglay ng antibodies na nakatutulong para palakasin ang immune response laban sa bacteria at viruses.

Sa ngayon, 17 ospital ang pinapayagan ng FDA na mag-administer ng convalescent plasma sa mga COVID-19 patients.

TAGS: convalescent plasma treatment, covid pandemic, COVID-19, COVID19 patients, department of health, doh, FDA, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, convalescent plasma treatment, covid pandemic, COVID-19, COVID19 patients, department of health, doh, FDA, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.